Ke et al. altered the tumor glucose supply and metabolic pathways by designing RGD-modified, RBC membrane-coated glucose oxidase (Gox) and DOX metal organic framework bioreactors (RGD-mGZD). This evidence concerns the gene HAO1 and neoplasm.